University of New Mexico

unm.edu

Total trials

310

Active

36

Phase 3

8

Total enrollment

1,108,901

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Dexamethasone2
Methylprednisolone2
2% Lidocaine HCl1
MDMA Assisted Therapy1
Psilocybin2
Tirzepatide1
Zinc Picolinate 15 Mg1

Next readouts

  • 2026-08
  • 2027-01-01
  • 2027-04
  • 2027-05-01
  • 2027-07

Top conditions

  • Cancer14
  • Obesity10
  • Lung Diseases8
  • Chronic Pain7
  • Contraception7
  • Depression6
  • Alcohol Use Disorder5
  • Diabetes Mellitus5

Frequently asked questions about University of New Mexico

How many clinical trials does University of New Mexico have on ClinicalTrials.gov?
University of New Mexico is listed as the lead sponsor on 310 clinical trials in ClinicalTrials.gov, 36 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of New Mexico's trials are in Phase 3?
8 of University of New Mexico's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does University of New Mexico focus on?
University of New Mexico's most-studied conditions on ClinicalTrials.gov are Cancer, Obesity, Lung Diseases, Chronic Pain, Contraception.
When are University of New Mexico's next clinical trial readouts?
University of New Mexico has 5 upcoming primary-completion readouts tracked here; the soonest is “Effect of Tirzepatide on Markers of MASLD in Patients With Obesity”, expected around 2026-08.